Delving into the Latest Updates on Shandong Lanjin Biological Engineering Co., Ltd. with Synapse

Overview

Basic Info

Introduction

Shandong Lanjin Pharmaceuticals Co.,Ltd. is strategically positioned at the heart of Jinan's High-Tech Zone, focusing on the research, development, and production of innovative anticancer pharmaceuticals, as well as the transfer of related technologies.

Tags

Nervous System Diseases

Neoplasms

Small molecule drug

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Nervous System Diseases	1
Hemic and Lymphatic Diseases	1
Neoplasms	1
Immune System Diseases	1

Top 5 Drug Type	Count

Small molecule drug	1

Top 5 Target	Count

DNA	1

评价卡莫司汀（BCNU）缓释植入剂治疗初发恶性脑胶质瘤的有效性和安全性。主要目的: 观察卡莫司汀缓释植入剂(CASANT)治疗初发恶性脑胶质瘤患者的总生存期（OS）。次要目的：观察卡莫司汀缓释植入剂(CASANT)治疗初发恶性脑胶质瘤患者的无进展生存期（PFS）和安全性。

[Translation]

To evaluate the efficacy and safety of carmustine (BCNU) sustained-release implant in the treatment of newly diagnosed malignant glioma. Primary objective: To observe the overall survival (OS) of patients with newly diagnosed malignant glioma treated with carmustine sustained-release implant (CASANT). Secondary objective: To observe the progression-free survival (PFS) and safety of carmustine sustained-release implant (CASANT) in the treatment of patients with newly diagnosed malignant glioma.

Start Date04 Jan 2015

Sponsor / Collaborator

Shandong Lanjin Biological Engineering Co., Ltd.

CTR20131097

/ RecruitingPhase 3

卡莫司汀缓释植入剂治疗复发恶性脑胶质瘤随机、双盲、安慰剂对照、多中心临床研究

[Translation] A randomized, double-blind, placebo-controlled, multicenter clinical study of carmustine sustained-release implant in the treatment of recurrent malignant brain glioma

评价卡莫司汀（BCNU）缓释植入剂治疗复发恶性脑胶质瘤的有效性和安全性。

[Translation]

To evaluate the efficacy and safety of carmustine (BCNU) sustained-release implant in the treatment of recurrent malignant brain glioma.

Start Date21 Oct 2013

Sponsor / Collaborator

Shandong Lanjin Biological Engineering Co., Ltd.

CTR20131931

/ RecruitingPhase 3

注射用盐酸苯达莫司汀治疗初治慢性淋巴细胞白血病的随机、开放、平行对照、多中心临床研究

[Translation] A randomized, open, parallel-controlled, multicenter clinical study of bendamustine hydrochloride for injection in the treatment of newly diagnosed chronic lymphocytic leukemia

评价苯达莫司汀单药对比苯丁酸氮芥治疗初治慢性淋巴细胞白血病的有效性和安全性

[Translation]

To evaluate the efficacy and safety of bendamustine alone versus chlorambucil in the treatment of newly diagnosed chronic lymphocytic leukemia

Start Date12 Apr 2011

Sponsor / Collaborator

Shandong Lanjin Biological Engineering Co., Ltd.

100 Clinical Results associated with Shandong Lanjin Biological Engineering Co., Ltd.

Login to view more data

0 Patents (Medical) associated with Shandong Lanjin Biological Engineering Co., Ltd.

Login to view more data

100 Deals associated with Shandong Lanjin Biological Engineering Co., Ltd.

Login to view more data

100 Translational Medicine associated with Shandong Lanjin Biological Engineering Co., Ltd.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 15 Sep 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Phase 3

1

Other

Login to view more data